Prevention of opportunistic infections in immune-compromised subjects
View Patent ↗This invention relates to a composition suitable for use in the prevention of opportunistic infections in immune-compromised individuals comprising a probiotic Bifidobacterium lactis, Bifidobacterium infantis, Bifidobacterium breve or Bifidobacterium longum and a fucosylated oligosaccharide selected from the group comprising 2′-fucosyllactose, 3′fucosyllactose, difucosyllactose, lacto-N-fucopentaose, lacto-N-fucohexaose, fucosyllacto-N-hexaose and fucosyllacto-N-neohexaose. The invention further extends to the use of such a composition in the prevention of opportunistic infections in immune-compromised individuals.
1. A composition suitable for use in the prevention of opportunistic infections in immune-compromised individuals, the composition comprising:
a probiotic selected from the group consisting of Bifidobacterium lactis CNCM I-3446 and Bifidobacterium longum ATCC BAA-999; and
a fucosylated oligosaccharide consisting of 2′-fucosyllactose, wherein the composition is selected from the group consisting of an infant formula and a supplement, and wherein the 2′-fucosyllactose is obtained by a process comprising a step selected from the group consisting of isolation from a natural source, chemical synthesis and biotechnological synthesis, and the 2′-fucosyllactose is present in an amount of 0.1 to 3 g per 100 g of the composition.
2. The composition of claim 1 , which is an infant formula.
3. The composition of claim 2 , which comprises from 10e3 to 10e12 cfu of the probiotic/g infant formula.
4. The composition of claim 2 , which comprises from 10e6 to 10e9 cfu of the probiotic/g infant formula.
5. The composition of claim 2 , which comprises at least one prebiotic in an amount of from 0.3 to 10% by weight of the composition.
6. The composition of claim 1 , which is a supplement and which comprises from 10e5 to 10e12 cfu of the probiotic per unit dose.
7. A composition suitable for use in the prevention of opportunistic infections in immune-compromised individuals, the composition comprising:
a probiotic selected from the group consisting of Bifidobacterium lactis CNCM I-3446 and Bifidobacterium longum ATCC BAA-999; and
a fucosylated oligosaccharide consisting of 2′-fucosyllactose, wherein the composition is selected from the group consisting of an infant formula and a supplement, and wherein the 2′-fucosyllactose is obtained by a process comprising a step selected from the group consisting of isolation from a natural source, chemical synthesis and biotechnological synthesis.